为您找到相关结果约225个

你是不是要搜索 期刊tralokinumab 点击跳转

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis

Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors

Long-term tralokinumab therapy in moderate to severe atopic dermatitis

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence

The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents

Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13

Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging

Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab

No clinically relevant hypersensitivity reactions in clinical trials with tralokinumab in asthma

Tralokinumab does not affect endogenous IL13Ra2-mediated regulation of free IL-13

Tralokinumab (Adtralza®), a new drug for atopic dermatitis.A new monoclonal antibody, tralokinumab, is available for the management of atopic dermatitis.

Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis

为您找到相关结果约225个

共225条页码: 2/15页15条/页